Wedbush Increases Earnings Estimates for TScan Therapeutics

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Wedbush increased their FY2028 EPS estimates for shares of TScan Therapeutics in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will earn $0.46 per share for the year, up from their previous forecast of $0.40. Wedbush currently has a “Outperform” rating and a $10.00 target price on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share.

TCRX has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of TScan Therapeutics in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of TScan Therapeutics in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Trading Down 8.5 %

NASDAQ TCRX opened at $4.41 on Thursday. TScan Therapeutics has a 1 year low of $3.73 and a 1 year high of $9.69. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 7.77. The company has a market capitalization of $233.62 million, a PE ratio of -4.16 and a beta of 0.79. The company has a fifty day moving average of $5.31 and a 200 day moving average of $6.49.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock worth $289,000 after acquiring an additional 44,903 shares during the last quarter. XTX Topco Ltd purchased a new position in TScan Therapeutics in the 3rd quarter valued at $112,000. Wellington Management Group LLP boosted its stake in TScan Therapeutics by 38.9% during the 3rd quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock worth $629,000 after purchasing an additional 35,404 shares during the last quarter. State Street Corp raised its position in shares of TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after buying an additional 148,414 shares during the last quarter. Finally, Stifel Financial Corp lifted its stake in shares of TScan Therapeutics by 3.9% in the third quarter. Stifel Financial Corp now owns 99,133 shares of the company’s stock worth $494,000 after buying an additional 3,733 shares in the last quarter. 82.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Barbara Klencke purchased 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was bought at an average price of $5.29 per share, with a total value of $26,450.00. Following the acquisition, the director now owns 45,000 shares in the company, valued at $238,050. The trade was a 12.50 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total transaction of $951,885.08. Following the transaction, the insider now directly owns 4,716 shares in the company, valued at approximately $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders acquired 15,000 shares of company stock valued at $82,550. 2.76% of the stock is owned by company insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.